TAHO Pharmaceuticals Ltd. announced the dosing of the first subjects in its U.S. Phase III clinical trial for its lead product, TAH3311, an innovative antithrombotic oral dissolving film (ODF). In ...

In the ever-evolving world of pharmaceutical development, the quest to innovate and improve the delivery of drug substances remains a top priority. Among the many formulation strategies, oral liquid ...

Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject ...

Sea's novel synthetic molecules act at the neurotransmitter glutamate pathway on two clinically validated targets in the central nervous system, "the CNS"Two potent, selective, pre-clinical stage ...

Health experts have warned that a deadly mouth cancer is on the rise - and suggested that a certain sex act has sparked an ...